Cific 1 (EC 2.7.1.30) R.WLLDNVR.K Glycine dehydrogenase [decarboxylating], mitochondrial P.RVNPLKMSPHSL.T Glycogen [starch] synthase, muscle (EC 2.4.1.11) T.KAKVTGDEWGDNYF.L Glycogen phosphorylase, brain form (EC 2.4.1.1) F.YELEPEKFQ.N D.LQIPPPNIPR.DP06737 Q96J90 Q8NFP4 O60551 P41250 Q14789 Q14789 Q08378 Q96S52 Q14444 Q96S75 Q9H2Q8 O60383 Q9C056 Q9UL65 O15068 P50151 Q14663 P00737 P00737 1 1 1 2 3
Cific 1 (EC 2.7.1.30) R.WLLDNVR.K Glycine dehydrogenase [decarboxylating], mitochondrial P.RVNPLKMSPHSL.T Glycogen [starch] synthase, muscle (EC 2.4.1.11) T.KAKVTGDEWGDNYF.L Glycogen phosphorylase, brain form (EC 2.4.1.1) F.YELEPEKFQ.N D.LQIPPPNIPR.DP06737 Q96J90 Q8NFP4 O60551 P41250 Q14789 Q14789 Q08378 Q96S52 Q14444 Q96S75 Q9H2Q8 O60383 Q9C056 Q9UL65 O15068 P50151 Q14663 P00737 P00737 1 1 1 2 3
Type-2 diabetics that can enhance prediction provided by established risk models. Our data were consistent with those presented in these studies. Functional tests have also been evaluated to screen asymptomatic diabetics. DIAD (Cardiac Outcomes after Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes) study [14] was a randomised trial that evaluated the impact of i